Navacaprant hydrochloride is under clinical development by Neumora Therapeutics and currently in Phase II for Bipolar II Disorder. According to GlobalData, Phase II drugs for Bipolar II Disorder does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Navacaprant hydrochloride LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Navacaprant hydrochloride overview

Navacaprant hydrochloride is under development for the treatment of bipolar II depression and major depressive disorder (MDD) with anhedonia. The drug candidate is a small molecule that acts by targeting kappa-type opioid receptor (KOR). It is administered through oral route in the form of tablet.

Neumora Therapeutics overview

Neumora Therapeutics is a biotechnology company that develops precision medications to treat patients suffering with brain diseases. The company is headquartered in Watertown, Massachusetts, the US.

For a complete picture of Navacaprant hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.